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Potential risk of disease 
modifying therapies on neoplasm 
development and coadjutant 
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outpatients
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Carmen Gómez‑Gómez1*
Neoplasm development in Multiple Sclerosis (MS) patients treated with disease‑modifying therapies 
(DMTs) has been widely discussed. The aim of this work is to determine neoplasm frequency, 
relationship with the prescription pattern of DMTs, and influence of the patients’ baseline 
characteristics. Data from 250 MS outpatients were collected during the period 1981–2019 from the 
medical records of the Neurology Service of the HUPM (Hospital Universitario Puerta del Mar)—in 
Southern Spain—and analysed using Cox models. Neoplasm prevalence was 24%, mainly located 
on the skin, with cancer prevalence as expected for MS (6.8%). Latency period from MS onset to 
neoplasm diagnosis was 10.4 ± 6.9 years (median 9.30 [0.9–30.5]). During the observation period 
β‑IFN (70.4% of patients), glatiramer acetate (30.4%), natalizumab (16.8%), fingolimod (24.8%), 
dimethyl fumarate (24.0%), alemtuzumab (6.0%), and teriflunomide (4.8%) were administered as 
monotherapy. Change of pattern in step therapy was significantly different in cancer patients vs 
unaffected individuals (p = 0.011) (29.4% did not receive DMTs [p = 0.000]). Extended Cox model: 
Smoking (HR = 3.938, CI 95% 1.392–11.140, p = 0.010), being female (HR = 2.006, 1.070–3.760, 
p = 0.030), and age at MS diagnosis (AGE‑DG) (HR = 1.036, 1.012–1.061, p = 0.004) were risk factors 
for neoplasm development. Secondary progressive MS (SPMS) phenotype (HR = 0.179, 0.042–0.764, 
p = 0.020) and treatment‑time with IFN (HR = 0.923, 0.873–0.977, p = 0.006) or DMF (HR = 0.725, 
0.507–1.036, p = 0.077) were protective factors. Tobacco and IFN lost their negative/positive influence 
as survival time increased. Cox PH model: Tobacco/AGE‑DG interaction was a risk factor for cancer 
(HR = 1.099, 1.001–1.208, p = 0.049), followed by FLM treatment‑time (HR = 1.219, 0.979–1.517). In 
conclusion, smoking, female sex, and AGE‑DG were risk factors, and SPMS and IFN treatment‑time 
were protective factors for neoplasm development; smoking/AGE‑DG interaction was the main cancer 
risk factor.
Although survival after the onset of Multiple Sclerosis (MS) has historically increased for 17 years, as reflected 
in the first works 41 years ago, patient life expectancy is, on average, 7 years below the general population  data1. 
While there are different estimations about the increased risk for all-cause mortality (up to threefold), everyone 
agrees that MS itself is the main cause of  death2,3.
Disease-modifying therapies (DMTs) have been the most important advance in MS treatment, from the 
so-called first-generation drugs, β-interferon (IFN) and glatiramer acetate (GA), approved in the mid-1990s, 
until the introduction of the latest drugs in the 2010s, such as fingolimod (FLM), alemtuzumab (ALB), dimethyl 
fumarate (DMF), teriflunomide (TRF), or the most recently approved purine analogue,  cladribine4. Despite their 
benefits, undesirable effects are expected, especially in relation to infection and  malignancy5. IFN liver failure or 
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progressive multifocal leukoencephalopathy from natalizumab (NTB), although not frequent, are seen as pos-
sible threats in routine clinical practice, unlike the development of neoplasms, a rare but dangerous side effect.
In the literature, we found a disparity in the data for both neoplasm frequency in MS patients and the role of 
DMTs in the neoplasm development, from an increase in cancer-related deaths (1.9-fold)6 to normal or decreased 
cancer prevalence, although the hazard risk depends on the type of  tumour7,8. Increased cancer risk has been 
observed among patients treated with IFN, GA, NTB, and  ALB9,10. The development of skin cancer is contem-
plated in the technical information about GA, FLM (basal cell and squamous cell skin cancers, Bowen’s disease, 
melanoma, Kaposi’s sarcoma), and ALB (papilloma) (available at http:// www. ema. europa. eu, European Medicines 
Agency, EMA, last accesed May 2021).
Therefore, the aim of this work is to investigate the therapeutic pattern followed and its relationship with 
the incidence of neoplasia in MS outpatients. We hypothesise that DMTs could constitute risk factors for the 
development of neoplasia. Patients’ baseline characteristics were considered for their possible contribution to 
the development of neoplasms.
Methods
Patient recruitment. This retrospective study was based on outpatients from the Department of Neurol-
ogy at the Hospital Universitario Puerta del Mar (HUPM), attended to in consultation from onset of MS between 
1981 and 2019. According to the Spanish Statistical Office, the area served by HUPM had an average popula-
tion of 220 thousand during this period (data available at  http:// www. ine. es, Instituto Nacional de Estadística, 
INE). The data source was the digital medical record used by neurologists conducting a multidisciplinary team. 
Other independently-trained team members carried out data extraction and statistical analysis. Individuals pre-
viously suffering from a neoplasm or diagnosed with Clinically Isolated Syndrome were excluded. As a result, 
314 consecutive cases were analysed, 250 of which fulfilled the inclusion criteria. The last case was diagnosed in 
September 2017, and the follow-up of patients ended on the last database registered individual (March 31, 2019).
Measures. The analysed variables were: (a) demographic and baseline characteristics: sex, age at MS onset 
(AGE-DG); disease phenotype; as possible contributing factors, neoplasm family history and smoking; (b) fac-
tors related to neoplasm development: presence and number of neoplasms; malignancy/benignity; tumour line-
age; age at neoplasm onset; latency period from the start of DMTs until neoplasm appearance c) factors related to 
the medication received: type and number of drugs; use order; treatment time for each drug; length of treatment.
Statistical analysis. Categorical variables were expressed as number and percentage of observed data; 
numeric variables were represented as mean ± standard deviation and median (minimum–maximum). Associa-
tion between categorical variables was contrasted by χ2 test, or if these conditions were not verified, by Fisher’s 
exact test. Quantitative variable comparisons were performed using the Student’s t-test. Associations were con-
sidered significant when p < 0.05. For each patient, the observation period (survival time) started with MS diag-
nosis until neoplasm appearance or the end of the study (censored case).
Several covariate analyses were performed to estimate the role of DMTs and other possible contributing fac-
tors to neoplasm development. The Cox proportional hazard model was used to analyse the predictors associated 
with the hazard rate (HR), with a 95% confidence interval (CI). For assessing the proportional hazard (PH) for 
each predictor of interest, we also estimated p-values between the ranked survival and the residuals. When the 
predictors did not satisfy the PH assumption, an extended Cox model was used. For this purpose, we included 
time-dependent variables to measure the interaction factor with time  exposure11. The data were processed using 
IBM SPSS Statistics 24 and Epidat 3.1 software.
Ethical considerations. The study was approved by the Comité de Ética de la Investigación de Cádiz. Ser-
vicio Andaluz de Salud. Consejería de Salud. Junta de Andalucía. HUPM. Av. Ana de Viya 21, 11009 CÁDIZ 
(SPAIN) (phone + 0034 956002100) (ceic.hpm.sspa@juntadeandalucia.es). The need of the informed consent 
was waived by the Comité de Ética de la Investigación de Cádiz. All the experiments were carried out in accord-
ance with the relevant guidelines and regulations.
Results
Patient baseline features. Patient baseline features were registered in Table  1. Women accounted for 
63.2% (n = 158) of the individuals. Mean AGE-DG was 34.0 ± 11.3 years (median 32.0 [13–71)], mostly ranging 
from 20–40 years (62.4%, n = 156). Relapsing–remitting variant (RRMS) (83.2%, n = 208) was the predominant 
medical condition. Neoplasm family history was present in 10.4% (n = 26) and tobacco consumption in 44% 
(n = 110) of individuals. In particular, 24% (n = 60) developed some kind of neoplasm, alone or successively. 
Five patients suffered from a second (n = 4) or a third process (n = 1). Out of the sampled patients, 6.8% (n = 17, 
28.3% of neoplastic patients) suffered malignancy and two of these individuals presented benign tumour. Mean 
age at tumour diagnosis was 46.2 ± 11.3 years (median 45.5 [26–80]) for neoplasm and 52.1 ± 8.4 for malignancy 
(median 53.0 [37–69]). Feminine gender, smoking, and family history were significantly present in neoplasm 
patients as compared to patients who did not present these characteristics (p < 0.05). Cancer patients were older 
at AGE-DG (39.8 ± 12.3 years, median 40 [21–64)] than the remaining individuals (33.58 ± 11.12, median 32.0 
[13–71], n = 233) (mean (p = 0.027), median (p = 0.043)).
Mean MS duration was 13.1 ± 7.8 years. Table 1 shows the observation periods. The latency period from MS 
to neoplasm appearance was 10.4 ± 6.9 years (median 9.30 [0.9–30.5]), significantly less than the observation 
period for censured cases (mean 12.8 ± 7.7, median 11.6 [1.3–37.5]) (mean p = 0.031, median p = 0.024).
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Tumour lineage. Table  2 indicates tumour frequency, site, developmental lineage, and cell line. Sixty 
patients developed some kind of neoplasm (n = 66), 74.2% were benign (n = 49), with melanocytic nevus (18.2% 
of neoplasms, n = 12) and uterine myoma (12.1%, n = 8) being most common. The most frequent locations were 
cutaneous tissue (keratosis, melanocytic nevus, melanoma, basal cell carcinoma) (37.9%, n = 25) and the myo-
metrium (12.1%, n = 8). The neoplasms originated in the ectoderm (65.2%, n = 43), mesoderm (27.3%, n = 18), or 
had a mixed origin (7.5%, n = 5). The epithelial cell line was most frequent (38.3% of neoplasm, n = 27), followed 
by the melanocytic line (21.2%, n = 14). Fourteen malignant tumours were carcinomas.
DMT pattern and neoplasm development. A total of 92.9% (n = 232) of individuals received DMTs, 
41.4% (n = 96) of which continued on their first therapy, while 58.6% (n = 136) was required to switch drugs due 
to inefficacy or non-compliance. According to clinical criteria, 18 patients remained untreated (mean AGE-
DG 47.1 ± 11.0, median 48.5 [29–67]; mean age at neoplasm diagnosis was 62.2 ± 5.1, median 62.5 [54–69]; 
44.4% women). The drugs administered as monotherapy were IFN (n = 176, 70.4% of patients), GA (n = 76, 
30.4%), NTB (n = 42, 16.8%), FLM (n = 62, 24.8%), DMF (n = 60, 24.0%), TRF (n = 12, 4.8%), and ALB (n = 15, 
6.0) (Table 3).
For the case of neoplastic patients, 10% did not receive treatment, while 36.7% (n = 22) were being treated 
with their first drug, 31.7% (n = 19) with a second drug, and 13 (21.7%) with a third, fourth, or fifth option, with 
no differences with respect to non-neoplastic patients. A total of 29.4% (n = 5) of cancer patients did not receive 
treatment vs cancer-free individuals (5.1%, n = 13) (p = 000), with differences between both groups also observed 
in the escalating therapy (p = 0.011) (Table 3).
Treatment duration, overall and specifically for each drug, is recorded in Table 3. Median treatment length 
was around eight years in all groups (whole sample 8.2 ± 5.6 years, median 8.3 [0.0–22.8]). IFN therapy had the 
longest duration of treatment (mean 4.6 ± 5.6 years, median 1.8 [0.0–22.0)]. Mean treatment time with DMF 
resulted significantly lower in neoplasm patients (mean 0.3 ± 0.7, median 0.0 [0–3.7]) vs unaffected individuals 
(mean 0.6 ± 1.1, median 0.0 [0.0–3.7]) (mean (p = 0.005), median (p = 0.43)).
Figure 1 shows the drug prescription frequency in sequential therapy for the whole sample (detailed in 
Table 3) as well as the four groups studied (NEO: patients with neoplasm, NNEO: neoplasm-free patients; 
CANCER: patients with cancer; NCANCER: cancer-free patients). IFN was the main first choice in all groups 
(64.8%, n = 162). As a second option, a wider range of drugs was prescribed, with GA being used significantly 
more in neoplastic (23.3%, n = 14) as compared to “healthy” patients (12.1%, n = 23) (p = 0.024). Individuals 
who received IFN as a third option had previously received it as a first option. Only one patient was required to 
change to a fifth drug (in the following order: IFN, GA, FLM, DMF, ALB) during the observation period and 
developed malignancy.
Table 1.  Patient baseline features. Comparison of individuals affected vs unaffected by neoplasia. *p value 
from the χ-test or T-test. § RRMS: relapsing–remitting MS; PPMS: primary progressive MS; SPMS: secondary 
progressive MS; PRMS: progressive-relapsing MS. ¥ Time from MS diagnosis to first neoplasm/cancer 
appearance or end of the observation period (censored cases). **TOTAL: whole sample; NEO: patients with 
neoplasm; NNEO: neoplasm-free patients; CANCER: patients with cancer; NCANCER: cancer-free patients.
TOTAL** (N = 250) NEO (n = 60) NNEO (n = 190) p* CANCER (n = 17)
NCANCER 
(n = 233) p*
Woman, n(%) 158 (63.2) 46 (76.7) 112 (58.9) 0.013 12 (70.6) 146 (62.7) 0.513
Age at onset
Mean ± SD 34.0 ± 11.3 35.6 ± 11.5 33.5 ± 11.2 0.205 39.8 ± 12.3 33.58 ± 11.12 0.027
Median (range) 32.0 (13–71) 34.0 (18–71) 32.0 (13–67) 0.271 40 (21–64) 32.0 (13–71) 0.043
Age Intervals, n(%) 0.264 0.085
 < 20 years 21 (8.4) 2 (3.3) 19 (10.0) 0 (0.0) 21 (9.0)
20–40 years 156 (62.4) 40 (66.7) 116 (61.1) 9 (52.9) 147 (63.1)
 > 40 years 73 (29.2) 18 (30.0) 55 (28.9) 8 (47.1) 65 (27.9)
MS phenotype, 
n(%) § 0.286 0.297
RRMS 208 (83.2) 51 (85.0) 157 (82.7) 12 (70.5) 196 (84.1)
PPMS 19 (7.6) 6 (10.0) 13 (6.8) 2 (11.8) 17 (7.3)
SPMS 21 (8.4) 2 (3.3) 19 (10) 2 (11.8) 19 (8.2)
RPMS 2 (0.8) 1 (1.7) 1 (0.5) 1 (5.9) 1 (0.4)
Smoking, n(%) 110 (44) 35 (58.3) 75 (39.5) 0.010 9 (52.9) 75 (39.5) 0.442
Neo family history, 
n(%) 26 (10.4) 11 (18.3) 15 (7.9) 0.021 2 (11.8) 24 (10.3) 0.849
Average follow-up time (years)¥
Mean ± SD 12.1 ± 7.6 10.4 ± 6.9 12.8 ± 7.7 0.031 12.2 ± 7.6 12.2 ± 7.6 0.992
Median (range) 11.2 (0.9–37.5) 9.4 (0.9–30.5) 11.6 (1.3–37.5) 0.024 9,9 (2.3–27.8) 11.2 (0.9–37.5) 0.972
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Cox proportional hazard risk (HR) models to evaluate the contribution of variables to neo‑
plasm development. Variables with statistical significance (p < 0.05) or no significance but with possible 
long-term influence (p < 0.15), estimated by the Wald test, are recorded in Table 4. The PH hypothesis was not 
admissible for smoking (TAB) (p(PH) = 0.046), duration of IFN use (TIFN) (p(PH) = 0.002), and covariates with 
p(PH)-values between 0.662–0.986. This was solved using an extended Cox model, including two time-depend-
ent covariates: a) survival time (ST) multiplied by TAB (STxTAB) and b) ST multiplied by TINF-r (STxTINF-
r) (TIFN was previously categorised as TINF-r = 0 and TINF-r > 0). HR values were constant throughout the 
follow-up period, except for variables TAB and TINF.
Using this model (Table 4), we found that for each increasing year of MS diagnosis, risk increases 3.6% 
(HR = 1.036, CI95% 1.012–1.061, p = 0.004), women have twice the risk than men (HR = 2.006, CI95% 
1.070–3.760, p = 0.030), and smoking quadruples the risk of development of a first neoplasm (HR = 3.938, CI95% 
1.392–11.140, p = 0.010). To a lesser extent, family history of neoplasm increased risk 1.7 times (HR = 1.711, 
CI95% 0.855–3.426, p = 0.0129). Secondary progressive MS (SPMS) was found to be a protective risk factor with 
≈1/5 the risk of neoplasm development with respect to other MS phenotypes (HR = 0.179, CI95% 0.042–0.764, 
p = 0.020).
TINF (HR = 0.923, CI95% 0.873–0.977, p = 0.006) or duration of DMF use (TDMF) (HR = 0.725, CI95% 
0.507–1.036, p = 0.077) acted as risk protectors in such a way that for each treatment year with IFM or DMF, 
neoplasm risk decreased by 8% or 27%, respectively. STxTAB (HR = 0.926, CI95% 0.849–1.011, p = 0.087) and 
STxTINF (HR = 1.055, CI95% 0.989–1.124, p = 0.102), shown as survival time (free-neoplasm time), modified 
the predicted risks so that with each passing year, both smoking risk and protective nature of TIFN decreased.
A second Cox proportional HR model analysed the predictors for cancer-free time (Table 4). AGE-DG 
(HR = 1.056, CI95% 0.998–1.117, p = 0.057) and TAB (HR = 0.040, CI95% 0.001–2.027, p = 0.108) influenced 
malignancy. Increased age at diagnosis raised the risk, while smoking appeared to be a protective factor. However, 
when variable-interaction effect was estimated (HR = 1.099, CI95% 1.001–1.208, p = 0.049), AGE-DG, as a risk 
factor, increased in smokers and TAB increased cancer risk as AGE-DG increased. Thus, smoking becomes a risk 
Table 2.  Neoplasm types and frequency. § MGUS: Monoclonal gammopathy of uncertain significance.
Neoplasm type (n=66) Frecuency n (%) Cell line Embryogenic lineage
BENIGN (n = 49, 74.2%)
Pleomorphic parotid adenoma 1 (1.5) Mixed Mixed
Hürtle cell thyroid adenoma 1 (1.5) Epithelial Ectodermal
Liver angioma 1 (1.5) Blood vessel Mesodermal
Renal angiomyolipoma 1 (1.5) Mixed Mixed
Breast fibroadenoma 3 (4.5) Mixed Mixed
Fibroma 2 (3.0) Connective Mesodermal
MGUS§ 1 (1.5) Hematopoietic Mesodermal
Ganglion (interphalangeal) 1 (1.5) Connective Mesodermal
Benign prostatic hyperplasia 1 (1.5) Epithelial Ectodermal
Lipoma 2 (3.0) Adipose tissue Mesodermal
Cerebral meningioma 2 (3.0) Meninges Mesodermal
Uterine myoma 8 (12.1) Myometrium Mesodermal
Acoustic neurilenoma 1 (1.5) Nervous tissue Ectodermal
Brachial plexus neurilenoma 1 (1.5) Nervous tissue Ectodermal
Common melanocytic nevus 12 (18.2) Melanocytes Ectodermal
Uterine endocervical polyp 1 (1.5) Epithelial Ectodermal
Hyperplastic colonic polyp 1 (1.5) Epithelial Ectodermal
Laryngeal polyp 1 (1.5) Epithelial Ectodermal
Gallbladder benign polyp 1 (1.5) Epithelial Ectodermal
Vocal polyp 1 (1.5) Epithelial Ectodermal
Actinic keratosis 1 (1.5) Epithelial Ectodermal
Seborrheic keratosis 5 (7.6) Epithelial Ectodermal
MALIGNANT (n = 17, 25.8%)
Breast adenocarcinoma 2 (3.0) Epithelial Ectodermal
Prostate Adenocarcinoma 2 (3.0) Epithelial Ectodermal
Lung adenocarcinoma 2 (3.0) Epithelial Ectodermal
Basal-cell carcinoma 5 (7.6) Epithelial Ectodermal
Papillary thyroid carcinoma 2 (3.0) Epithelial Ectodermal
Ovarian serous Carcinoma 1 (1.5) Epithelial Ectodermal
Melanoma 2 (3.0) Melanocytes Ectodermal
Chronic myeloid leukaemia 1 (1.5) Hematopoietic Mesodermal
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factor for patients over the sampled mean age (34 years). Note that at this age, the HR of TAB + AGE-DG TAB is 
exp(− 3.228 + 34 * 0.095) = 1.002. Finally, duration of FLM use was a risk factor (HR = 1.219, CI95% 0.979–1.517, 
p = 0.077) for cancer development.
Discussion
Are detected frequency and malignancy type similar to that of the general population? In the European 
 population12, breast (13.5% of all cancer cases), prostate (12.1%), and lung cancer (11.9%) represent 37.5% of all 
tumours, in a similar proportion to our data (35.3% of cancers, n = 7). However, in our sample, skin melanoma 
represented 11.8% (2 of 17), while, in Europe, it is the sixth most frequent cancer (3%); although non-melanoma 
skin cancer (particularly basal cell carcinomas) data were similar in sampled individuals (71.4% of cutaneous 
cancers) vs the general population (70–80%).
We detected 21 types of benign neoplasms, many of them common in individuals over the age of 50: MEGUS 
in 1% > 50; Hürtle-cell adenoma of the thyroid in 0.5–1% of adults; hyperplastic colonic polyps in 30% of adults, 
50% in the  elderly13. Uterine myoma was the second most frequent neoplasm in the patients sampled, in conso-
nance with myometrial tumours representing 20% of benign tumours in women (in our sample, 23.3% [n = 8] 
of 37 women suffered from benign processes)14.
Several studies suggested an increased risk of breast and central nervous system cancer, or benign neoplasm 
(meningioma, adenoma), but not especially skin  cancer7,9,15. On the contrary, other works detected a decreased 
 HR16: intense MS immune activity or immunomodulatory treatment has been hypothesised as an  explanation17. 
In this sense, the Cox analysis showed that increased age at MS onset implied a greater risk of both neoplasm 
Table 3.  Differences in therapy pattern between neoplasm-affected and unaffected patients.
Drug n (%) Total n = 250 NEO (n = 60) No NEO (n = 190) p CANCER (n = 17)
No CANCER 
(N = 233) p
None 18 (7.2) 6 (10) 12 (6.3) 0.336 5 (29.4) 13 (5.6) 0.000
INF 176 (70.4) 42 (70) 134 (70.5) 0.938 10 (58.8) 166 (71.2) 0.279
GA 76 (30.4) 23 (38.3) 53 (27.9) 0.125 4 (23.5) 72 (30.9) 0.524
NTB 42 (16.8) 9 (15.0) 33 (17.4) 0.669 2 (11.8) 40 (17.2) 0.565
FLM 62 (24.8) 15 (25.0) 47 (24.7) 0.967 5 (29.4) 57 (24.5) 0.648
DMF 60 (24.0) 9 (15.0) 51 (26.8) 0.061 3 (17.6) 57 (24.5) 0.525
TRF 12 (4.8) 4 (6.7) 8 (4.2) 0.438 0 (0.0) 12 (5.2) 0.338
ALB 15 (6.0) 2 (3.3) 13 (6.8) 0.318 1 (5.9) 14 (6.0) 1.000
No. of drugs admin-
istered, n (%) 0.813  0.011
0 18 (7.2) 6 (10) 12 (6.3) 5 (29.4) 13 (5.6)
1 96 (38.4) 22 (36.6) 74 (38.9) 3 (17.6) 92 (39.5)
2 82 (32.8) 19 (31.7) 63 (33.2) 7 (41.2) 76 (32.6)
> 2 54 (21.6) 13 (21.7) 41 (21.6) 2 (11.8) 52 (22.3)
Treatment length (years)
Mean ± SD 8.2 ± 5.6 8.8 ± 6.0 8.1 ± 5.5 0.500 8.3 ± 6.9 8.2 ± 5.5 0.865
Median (range) 8.3 (0.0–22.8) 8.7 (0.0–22.8) 8.0 (0.0–22.4) 0.412 8.9 (0.0–22.0) 8.3 (0.0–22.8) 0.977
Treatment length of each drug (years)
Mean ± SD Median (range)
IFN 4.6 ± 5.6 1.8 (0.0–22.0)
GA 1.5 ± 3.1 0.0 (0.0–13.3)
NTZ 0.7 ± 2.0 0.0 (0.0–9.8)
FLM 0.8 ± 1.6 0.0 (0.0–7.5)
DMF 0.5 ± 1.0 0.0 (0.0–3.7)
TLF 0.1 ± 0.5 0.0 (0.0–3.6)
ALB 0.1 ± 0.5 0.0 (0.0–3.0)
Drug prescribing frequency in the successive changes on sequential therapy
At 1st At 2nd At 3rd At 4th At 5th
n (%) (referred to whole sample [n = 250])
IFN 162 (64.8) 14 (5.6) 4 (1.6) 0 0
GA 38 (15.2) 37 (14.8) 0 1 (0.4) 0
NTB 7 (2.8) 23 (9.2) 10 (4.0) 2 (0.8) 0
FLM 6 (2.4) 28 (11.2) 25 (10.0) 3 (1.2) 0
DMF 14 (5.6) 29 (11.6) 9 (3.6) 8 (3.2) 0
TRF 2 (0.8) 5 (2.0) 4 (1.6) 1 (0,4) 0
ALB 3 (1.2) 1 (0.4) 3 (1.2) 7 (2.8) 1 (0.4)
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Figure 1.  Drug prescription frequency in the therapeutic sequence. Percentages were calculated in relation to 
the group total cases.
Table 4.  Cox analysis to assess the risk of neoplasm development. AGE-DG: age at MD diagnosis; GEN: 
gender; TAB: smoking; HYS: family history of neoplasm; SPMS: secondary progresive MS phenotype; TINF: 
time of INF use; TDMF: time of DMF use; TFLM: time of FLM use; ST: survival time (neoplasm-free time). 
*We have included non-significant p (PH)-values to contrast each covariate.
Coef SE Wald p HR 95% CI for HR
Extended Cox model to evaluate influence of covariates on the of the first neoplasm 
appearance
AGE-DG 0.035 0.012 8.417 0.004 1.036 1.012–1.061
GEN 0.696 0.321 4.718 0.030 2.006 1.070–3.760
TAB 1.371 0.531 6.675 0.010 3.938 1.392–11.140
HYS 0.537 0.354 2.302 0.129 1.711 0.855–3.426
SPMS -1.723 0.742 5.396 0.020 0.179 0.042–0.764
TINF -0.080 0.029 7.682 0.006 0.923 0.873–0.977
TDMF -0.322 0.182 3.119 0.077 0.725 0.507–1.036
ST x TAB -0.076 0.045 2.930 0.087 0.926 0.849–1.011
ST x TINF 0.053 0.033 2.667 0.102 1.055 0.989–1.124
Sample size = 250; − 2LnLikelihood = 524.849; LR (M1-M0) = 45.849 (9df) ; p = 0.000
Coef SE Wald p HR 95% CI for HR p(PH)*
Cox regression model to estimate influence of covariates in malignancy
AGE-DG 0.055 0.029 3.626 0.057 1.056 0.998–1.117 0.129
TAB -3.228 2.008 2.586 0.108 0.040 0.001–2.027 0.849
TFLM 0.198 0.112 3.126 0.077 1.219 0.979–1.517 0.133
AGE-DG x TAB 0.095 0.048 3.885 0.049 1.099 1.001–1.208 0.675
Sample size = 250; − 2LnLikelihood = 133.865; LR (M1-M0) = 22.411 (9df) ; p = 0.000
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and malignancy. Would this be due to a “protective” effect of the MS treatment, or to senility itself? Untreated 
patients were older; both at MS onset and cancer diagnosis, and 27.8% developed cancer, a higher value than 
the 13.92% for a Spanish population ≥ 65 under multi-morbidity  conditions18.
Moreover, a population-based study (51% women; mean age 47.76 ± 10.99, 77% population > 24 years old) 
reported a prevalence of 3%19. Despite this, cancer prevalence in our sample (6.8%) was in the range of 2.6–7.3% 
recorded in the MS  literature10,16,20. Neoplasm type and relative frequency were those expected in the general 
population, except for skin tumours (37.9%, 25 of 66 of neoplasms diagnosed), being the most prevalent. This 
is an expected side-effect of DMTs, recorded in the adverse reactions section of the Summary of Product Char-
acteristics for some drugs such as FLM, as mentioned above, or GA: ≥ 1/100 to < 1/10 of GA-treated patients 
could develop benign skin neoplasms; ≥ 1/1000 to < 1/10 could develop skin cancer. Technical information on 
other more recently introduced active substances such as NTB (00’) and ALB (10’s) includes a recommendation 
for additional monitoring for any suspicious reaction detected (http:// www. ema. europa. eu), but this is rather 
directed at other health-compromising side-effects (hepatic, immunological, or haematological effects). How-
ever, NTB has been directly linked to melanoma replication, invasion, and migration via blockage of α4-integrin 
expressed in tumour cells, and to the development of melanoma in treated  patients21.
Epidemiological studies on DMTs show data  disparity4, although second-line immunosuppressants (aza-
thioprine, cyclophosphamide, mitoxantrone) seem to involve a heightened risk for  malignancy22. However, the 
relationship between immunotherapy and neoplasm development is inconclusive since some of these drugs are 
employed as coadjuvants or even anti-cancer drugs (ALB, cladribine, mitoxantrone) (http:// www. ema. europa. 
eu), or are under consideration (FLM, TER) as oncologic therapeutic  options7,23. This implies their subjection 
by Medicines Agencies to the monitoring of the possible development of malignancy in treated MS patients. For 
example, in the safety analysis recorded in the technical information, the overall incidence of cancer was twofold 
higher in cladribine-treated patients compared to patients who received a placebo (http:// www. ema. europa. eu)24. 
It should be also highlighted that our patients will use them long-term.
Moreover, we found in our sample that TIFN and TDMF protected against neoplasm development, although 
INF and GA have been linked to cancer  development9,25–27. However, a regressive effect of IFN has been casu-
ally observed in isolated  neoplasms28, as well as a 32% lower mortality related to untreated  patients29. Regarding 
DMF, which was recently licensed, a few studies have been published with a short follow-up, confirming its safe 
use (cancer was detected in only 0.9% of patients)30.
On the other hand, as we estimated (HR = 1.219, p = 0.077), a high risk could be expected from FLM use, sup-
ported by register-based cohort  studies31,  reviews27, or technical information: basal cell carcinoma being common 
(≥ 1/100– < 1/10), squamous cell carcinoma being uncommon (≥ 1/1000- < 1/100), Kaposi’s sarcoma or Merkel 
cell carcinoma, as well as cases of lymphoma being rare (≥ 1/10,000– < 1/1000) (http:// www. ema. europa. eu).
SPMS acted as a protective factor for neoplasm development, but large retrospectives studies did not find 
differences in phenotype contribution with respect to a decrease in cancer  risk32. A possible explanation for our 
finding could be the distinct cytokine and adhesion molecule expression pattern of MS  variants33. This should 
be extensively examined. Likewise, the influence of the patient’s disability status on the neoplasm development 
could be considered. The latter is a limitation of our study and, although we did not include this variable like 
many other papers, some authors have found a low disease process, according to the Expanded Disability Status 
Scale (EDSS)(≤ 2), in the majority of patients with benign  tumours15.
Finally, to understand the extent of neoplasm development in MS patients, genetic predisposal factors and 
lifestyle must be explored, although some works observe a lack of information in this  regard22. Multivariate 
analysis revealed smoking to be the most significant risk predictor for neoplasm/cancer. Female sex is a risk 
factor; however, it should be noted that women predominated in our study (19.4%, 13 of 66 had gynaecological 
neoplasms). Family predisposition was a moderate risk predictor. In fact, a comprehensive study showed that 
lower cancer risk in MS patients did not coincide with a lower risk in their  parents34.
Conclusions
In the patients studied, neoplasm prevalence was 23.4%, with a similar distribution of different types of tumours 
with respect to the general population, except for skin neoplasm (37.9% of occurring neoplasms). In our sam-
ple, 6.8% of patients suffered from cancer, in line with the data observed in other MS-focused studies. The 
extended Cox model identified smoking as the main risk factor for neoplasm development (HR = 3.938, CI 
95% 1.392–11.140, p = 0.010), followed by the female gender (HR = 2.006, p = 0.030), and age at MS diagnosis 
(HR = 1.036, p = 0.04). SPMS (HR = 0.179, 0.042–0.764, p = 0.020) and treatment time with IFN (HR = 0.923, 
0.873–0.977, p = 0.006) or DMF (HR = 0.725, p = 0.077) were protective factors. Tobacco and IFN treatment 
time lost their negative/positive influence as the result of an increase in survival time. The Cox regression model 
identified tobacco/AGE-DG a risk factor for cancer (HR = 1.099, CI95%1.001–1.208, p = 0.049), followed by FLM 
treatment time (HR = 1.219, p = 0.077).
In summary, genetic factor, lifestyle, the inflammatory profile of MS, drug type, and clinical practice interact 
in a complex manner. The last drugs introduced would require more clinical experience. Perhaps, exposure time 
of these risk factors should be taken into account, given the long-term nature of the disease.
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